BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Israeli forces kill one person in series of attacks on southern Lebanon - 2'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- 3Viable Correspondence: Building Solid Connections
- 4Ancient eggshells shed new light on crocodiles that hunted prey from trees
- 5Vote In favor of Your Favored Web-based Visual depiction Administration
- Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Productive CRM Programming for Client Relationship The executives
- First part of major new German-Danish tunnel cleared for lowering
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- Working out at the airport? Some fliers can already smell the sweat.
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
